Châtillon, France, October 18, 2024 DBV Technologies to Participate in Upcoming ACAAI 2024 Congress DBV Technologies ...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that five abstracts have been accepted for e-Poster ...

Châtillon, France, October 18, 2024 DBV Technologies to Participate in Upcoming ACAAI 2024 Congress DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage ...

Asthma & Immunology’s (ACAAI) 2024 Annual Scientific Meeting, held in Boston from October 24-28, 2024. The company plans to present data up to 9 months from the ongoing Phase 1 clinical trial of ...

Asthma & Immunology's (ACAAI) 2024 Annual Scientific Meeting, held in Boston from October 24-28, 2024. The company plans to present data up to 9 months from the ongoing Phase 1 clinical trial of ...

In anticipation of the 2024 ACAAI Annual Scientific Meeting, Ruchi Gupta, MD, highlights advances in food allergy and gastrointestinal disorder management. This year, Dr Gupta is particularly ...

Dubai Studio City, the Middle East's leading hub for content creation, is nurturing pathways for creative talent to unlock ...

With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help tech journalists and consumers stay on top of the week's most newsworthy ...

BioCryst Pharmaceuticals' upcoming presentations at the ACAAI Annual Scientific Meeting align with the company's recent financial performance and market position. According to InvestingPro data ...

Dr Gupta previews the 2024 ACAAI Annual Scientific Meeting, where she is anticipating updates on the first FDA-approved biologic therapy for food allergies, along with other advancements in ...

ZUG, Switzerland, Oct. 16, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will present new three-year data from the Phase 2 open-label extension (OLE) study as well as additional results from the pivotal ...